Geographic Atrophy: Billing New Therapies

Geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (AMD), affects millions worldwide and leads to progressive central vision loss through atrophy of retinal layers. Recent FDA approvals of complement inhibitors like pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) mark a breakthrough, slowing GA lesion growth by up to 30%. Ophthalmologists must navigate precise coding and documentation for reimbursement, as payers scrutinize these high-cost intravitreal injections amid rising GA incidence projected to impact over 8 million globally.

Understanding GA Pathophysiology and Epidemiology

GA involves sharply demarcated atrophy of the outer retina, retinal pigment epithelium (RPE), and choriocapillaris, often starting perifoveally and expanding to the fovea, causing central scotomas. Affecting about 20% of late-stage AMD patients, GA prevalence rises with aging populations, with risk factors including older age, poor baseline visual acuity (e.g., ≥20/200 triples risk), hypercholesterolemia, and reticular pseudodrusen. Progression varies, with median growth of 2.1 mm²/year, accelerating in multifocal lesions or high hyperautofluorescence areas.

Complement pathway dysregulation drives GA, with genetic variants like CFH Y402H and ARMS2 implicated, alongside oxidative stress and inflammation evidenced by subretinal phagocytes and cytokines. Unlike wet AMD’s neovascularization, GA’s ‘dry’ nature previously lacked approved therapies, but new agents target C3/C5 to curb inflammation.

FDA-Approved Treatments: Mechanisms and Efficacy

Syfovre (pegcetacoplan), approved February 2023, inhibits C3, reducing activated convertases and downstream inflammation; monthly or every-other-month dosing slows GA growth by 20-36% over 24 months per DERBY/OAKS trials. Izervay (avacincaptad pegol), approved August 2023, blocks C5; monthly dosing yields 14-29% reduction in lesion growth in GATHER2. Both extend time to fovea involvement and vision loss, though they do not reverse damage.

Real-world adoption requires J-code billing: J2781 for Syfovre (1 mg), with 15 mg/0.1 mL vial; J3490 initially for Izervay until permanent code.

Accurate Coding for GA Diagnosis and Injections

Primary ICD-10 code H25.40 (Unspecified age-related macular degeneration, geographic atrophy) mandates laterality: H25.41 (right eye), H25.42 (left), H25.43 (bilateral). Pair with severity: H25.4111 (early dry AMD) escalates to H25.4133 (advanced atrophic). Exclude wet AMD codes (H35.32) unless mixed; document GA predominance.

• Use fundus autofluorescence (FAF), OCT for lesion size ≥1.25 mm² (extrafoveal) or ≥0.5 mm² (foveal).
• Confirm cRORA via OCT: ≥250 µm hypertransmission, RPE disruption, photoreceptor loss.
• Avoid overcoding; payers deny without progression proof.

Intravitreal injection CPT: 67028 (unpreserved formulation). Append modifiers: -RT/-LT for laterality, -25 for E/M same day. NDC for drug: Syfovre 79471-0304-10.

Documentation Essentials for Payer Approval

Payers demand GA-specific notes: lesion maps via FAF/OCT, growth rate (e.g., >0.5 mm²/year), fovea threat. Template: “Well-circumscribed GA lesion 2.3 mm² temporal to fovea on FAF; progression 1.8 mm²/12 mo on serial OCT; Syfovre indicated per DERBY data.”

Address prior auth hurdles:

• Medicare: Local Coverage Determination (LCD) L39041 requires fundus photography, FAF, microperimetry.
• Commercial: Pre-cert visual acuity <20/60, lesion >1 disc area.
• Appeal denials with trial data showing 29% growth slowing.

Payer Policies and Coverage Landscape

Medicare Part B covers under Outpatient Prospective Payment System (OPPS); APC 5733 (~$1,200 facility fee) + drug pass-through (~$2,100 Syfovre). CMS flags high-cost biologics; ensure A-scan biometry if concurrent cataract (66821-EG).

Private payers vary:

• UnitedHealthcare: Step therapy absent; requires GA confirmation via multimodal imaging.
• Anthem: Bilateral injections same session? Bill 67028-50.
• Aetna: Limits 12 doses/year initially.

Track MAC policies; Noridian JL supports 67028 + H25.41×3 for advanced GA.

Billing Pitfalls and Compliance Strategies

Avoid pitfalls:

1. Missing laterality: Always -RT/-LT; 30% denials.
2. Inadequate imaging: Submit FAF/OCT reports; color fundus alone insufficient.
3. Drug waste: Bill partial vial with JW modifier (e.g., 10 mg used, 5 mg discarded).
4. Audit triggers: High-volume injectors face RAC review; maintain 2-year records.

Pro tips: Use EHR macros for GA templates; co-bill 92134 (OCT) if diagnostic; global period 10 days post-injection—no E/M unless complication.

Future Directions in GA Management and Reimbursement

Ongoing trials explore oral complement inhibitors, gene therapy; biosimilars may lower costs by 2028. AOA/AAO advocate uniform LCDs; track QPP MIPS for GA metrics (e.g., imaging within 12 mo).

Low-vision rehab billing: 92071 (contact lens fitting) + S9980 (low-vision aids) complements therapy.

Frequently Asked Questions (FAQs)

GA therapy billing demands precision amid ~1 million U.S. cases; proactive documentation ensures revenue while advancing care.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete